[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PhilipHemme Avatar @PhilipHemme Philip Hemme

Philip Hemme posts on X about $bntx, $gmab, $mrus, breakthrough the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXXX% cryptocurrencies XXXX%

Social topic influence $bntx #2, $gmab #10, $mrus #10, breakthrough 4.35%, $argx #5, $asnd #2, $sobi #1, $abvx #23, $zeal #6, $camrf #1

Top accounts mentioned or mentioned by @peterkolchinsky @lifescivc @drrichjlaw @applehelix @livemunro @robotaxi @bertrandbio @grok @pmsyyz @lumicksnl @lovabledev @cutissag @elonmusk @wangzjeff @veronapharma @trungtphan @abivax @racapitalmgmt @harrystebbings @cutiss_ag

Top assets mentioned Merus N.V. Common Shares (MRUS) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Amgen, Inc. (AMGN) Summit Therapeutics Inc. Common Stock (SMMT) Baklava (BAVA) Merck & Co., Inc. (MRK) Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Morgan Stanley (MS) Bitcoin Incognito (XBI)

Top Social Posts #

Top posts by engagements in the last XX hours

"Paying high prices fuels drug innovation Amgen $AMGN still made $3.3B in 2024 from Enbrel a 27-year-old drug off-patent since 2016 with XX% of sales in the US. Not sure if price caps like Colorados are the fix but it might help Thoughts @PeterKolchinsky @LifeSciVC"
X Link @PhilipHemme 2025-10-04T04:30Z 6262 followers, 1646 engagements

"NEWS: BioNTech ( $BNTX) just unveiled positive interim Ph2 results for its PD-L1VEGF bispecific. A potential blockbuster and strong challenger to Summit ( $SMMT) & 3SBio 👀"
X Link @PhilipHemme 2025-09-09T04:02Z 6262 followers, 1791 engagements

"Why it matters These outcomes outperform the current standard in SC lung cancer (Roches Tecentriq + chemo) and boost confidence in the Ph3 program. Pumitamig has blockbuster potentialand could eventually pair with or even replace chemo through ADC combinations including those BioNTech is developing in-house"
X Link @PhilipHemme 2025-09-09T04:02Z 6261 followers, XXX engagements

"Context: The data follow the massive June 2025 deal between BioNTech and BMS ($1.5B upfront). Competition is fierce with rival PD-(L)1VEGF bispecifics from Akeso/Summit and Pfizer/3SBio advancing fast as well. The update also comes shortly after a Ph3 ADC win reinforcing BioNTechs growing oncology footprint. Despite the clinical progress the stock spiked XX% on the news before falling back to baseline"
X Link @PhilipHemme 2025-09-09T04:02Z 6261 followers, XXX engagements

"Big private takeover for $BAVA"
X Link @PhilipHemme 2025-07-29T01:11Z 6261 followers, XXX engagements

"NEWS: Genmab $GMAB acquires Merus $MRUS in one of the biggest biotech acquisitions in European biotech ever. $8B all cash Megadeal"
X Link @PhilipHemme 2025-09-29T11:33Z 6261 followers, XXX engagements

"EPISODE: Raising a $60M Series C in 2025 is tough. Daniela just did it to bring a breakthrough tissue therapeutic to the market The funding round is a testament to the fact that when there is a good product with good science and a clear unmet need.it is possible to find the right investors said CEO and co-founder Daniela Marino. She explains how @Cutiss_AG is building a decentralised production model for its tissue therapeutic that could replace skin grafts for severe burns. You can be as close as you can to the largest hospitals and try to serve the patients in a quicker and cheaper way. She"
X Link @PhilipHemme 2025-10-14T08:00Z 6261 followers, XXX engagements

"Lillys $LLY GLP-1 best selling drug ever in Q2 2025 🤑 Novo $NVO just behind slightly below Merck $MRK"
X Link @PhilipHemme 2025-10-04T03:39Z 6261 followers, XXX engagements

"What The acquisition centers on bispecific petosemtamab Merus breakthrough head and neck cancer drug with two FDA Breakthrough Therapy Designations and potential $1+ billion annual sales by 2029. Genmab will pay XX% premium funded through cash and $XXX billion in debt financing from Morgan Stanley. Why it matters The deal gives Genmab four proprietary programs expected to drive multiple new drug launches by 2027 and accelerates its transformation into a fully integrated biotechnology leader. Context: This is the largest acquisition in Genmabs history following the acquisition of ProfoundBio"
X Link @PhilipHemme 2025-09-29T11:33Z 6261 followers, XXX engagements

"Which biotech didn't you know 🤔 Top 10: $ARGX $BNTX $GMAB $ASND $SOBI $ABVX $MRUS $ZEAL $CAMRF $MLTX. $XBI"
X Link @PhilipHemme 2025-09-16T08:43Z 6261 followers, 43K engagements

"Who are the biggest biotechs in Europe 🤩 Want access to the data 👉 Want full access to the data in a digital web appwith list view market caps pipelines and therapeutic areas Comment Map and Ill send it to you rapidly 💬 Top 10: $ARGX $BNTX $GMAB $ASND $SOBI $ABVX $MRUS $ZEAL $CAMRF $MLTX"
X Link @PhilipHemme 2025-09-15T08:02Z 6261 followers, 1881 engagements